ABL-407

N/A

Report date: 2024/07/05 10:51:01

Base Information

Drug NameABL-407

Drug Alias NameABL-407ABL407

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4Anti-Tumor necrosis factor receptor superfamily member 9T lymphocytes stimulants +[4]

TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4Tumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A